Results 81 to 90 of about 24,193 (235)

Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway [PDF]

open access: yes, 2010
Autotaxin, encoded by the Enpp2 gene, generates lysophosphatidic acid (LPA) extracellularly, eliciting various cellular responses through specific LPA receptors.
Keino-Masu Kazuko   +4 more
core   +1 more source

Inconsistent Transcriptomic Responses to Hexabromocyclododecane in Japanese Quail: A Comparative Analysis of Results From Four Different Study Designs

open access: yesEnvironmental Toxicology and Chemistry, EarlyView.
Abstract Efforts to use transcriptomics for toxicity testing have classically relied on the assumption that chemicals consistently produce characteristic transcriptomic signatures that are reflective of their mechanism of action. However, the degree to which transcriptomic responses are conserved across different test methodologies has seldom been ...
Paul Béziers   +10 more
wiley   +1 more source

Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists

open access: yesCommunications Biology
Lysophosphatidic acid receptor 1 (LPA1) is one of the G protein-coupled receptors activated by the lipid mediator, lysophosphatidic acid (LPA). LPA1 is associated with a variety of diseases, and LPA1 agonists have potential therapeutic value for treating
Hiroaki Akasaka   +3 more
doaj   +1 more source

Enhancing adult hippocampal neurogenesis with lysophosphatidic acid: a proposal for erasing cocaine contextual memory [PDF]

open access: yes, 2018
Stimulating adult hippocampal neurogenesis (AHN) has been uncovered as a promising approach in the manipulation of retrograde memories. This work aims to study whether increasing AHN with lysophosphatidic acid (LPA, an endogenous lysophospholipid with ...
Castilla Ortega, María Estela   +9 more
core  

Expression profiles of TRPV1, TRPV4, TLR4 and ERK1/2 in the dorsal root ganglionic neurons of a cancer-induced neuropathy rat model

open access: yes, 2018
Background: The spread of tumors through neural routes is common in several types of cancer in which patients suffer from a moderate-to-severe neuropathy, neural damage and a distorted quality of life.
Elsadek, Bakheet, Maqboul, Ahmad
core   +2 more sources

Primary human endothelial cells secrete agents that reduce responsiveness to lysophosphatidic acid (LPA) [PDF]

open access: yes, 2012
The plasma level of LPA (lysophosphatidic acid) (200–600 nM) is well within the range that promotes proliferation and migration of vascular ECs (endothelial cells), yet vessels are quiescent and stable.
Kazlauskas, Andrius, Park, Eun Young
core   +3 more sources

CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake

open access: yeseLife
Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well ...
Savvas Nikolaou   +8 more
doaj   +1 more source

In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay

open access: yesFrontiers in Pharmacology, 2023
Lysophosphatidic acid (LPA) is a bioactive phospholipid that acts as an agonist of six G protein-coupled receptors named LPA receptors (LPA1-6).
C. Ruzza   +7 more
doaj   +1 more source

Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation [PDF]

open access: yes, 2005
Oxidation of low-density lipoprotein (LDL) generates proinflammatory and prothrombotic mediators that may play a crucial role in cardiovascular and inflammatory diseases.
Berliner JA   +23 more
core   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

open access: yesiMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy